Analysis of Medication Abortion Risk and the FDA report (ANSIRH)
Summary
The FDA report “Mifepristone U.S. PostMarketing Adverse Events Summary through 12/31/2018” includes adverse events associated with the use of mifepristone, regardless of their likelihood of being causally linked to the abortion.1 Over 3.7 million US women have used medication abortion with mifepristone and misoprostol since Mifeprex (mifepristone 200 mg) was first approved by the US Food and Drug Administration (FDA) in 2000. Since then, the safety of the treatment has been reaffirmed by rigorous research that supplements monitoring data from the FDA.
